Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs

CME Part I Psoriasis: Which Therapy for Which Patient Psoriasis comorbidities and preferred systemic agents

(2018) Shivani B. Kaushik et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

CME Part II Psoriasis: Which Therapy for Which Patient Focus on special populations and chronic infections

(2018) Shivani B. Kaushik et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Commentary: Does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality?

(2018) Joel M. Gelfand   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Comparison of Rates of Active Tuberculosis Infection in the Phase 2 and 3 Clinical Trial Programs for Anti-IL12/23 and Anti-TNFS

(2017) Edward V. Loftus et al.   GASTROENTEROLOGY

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies

(2016) Ari Polachek et al.   ARTHRITIS CARE & RESEARCH

Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic

(2015) Eric Sorenson et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

(2015) Richard B. Warren et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial

(2015) Arthur Kavanaugh et al.   ARTHRITIS CARE & RESEARCH

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

(2014) Christopher Ritchlin et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris

(2014) R. Gniadecki et al.   BRITISH JOURNAL OF DERMATOLOGY

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

(2013) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

(2013) Iain B McInnes et al.   LANCET

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

(2012) A.B. Kimball et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Discovery and mechanism of ustekinumab

(2012) Jacqueline M. Benson et al.   mAbs

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reversible Posterior Leukoencephalopathy Syndrome in a Patient Treated With Ustekinumab

(2011) David Gratton   ARCHIVES OF DERMATOLOGY

Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study

(2011) W.-Q. Li et al.   BRITISH JOURNAL OF DERMATOLOGY

Cardiovascular Disease and Risk Factors in Patients with Psoriasis and Psoriatic Arthritis

(2010) A.-M. TOBIN et al.   JOURNAL OF RHEUMATOLOGY

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

(2009) Alice Gottlieb et al.   LANCET

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET